US halts plasma study to treat mild COVID-19 citing 'unlikely benefit' - Fox News

Mutual Fund and ETF data provided by Refinitiv Lipper.

25 to assess trial data, and concluded that while the plasma "caused no harm, it was unlikely to benefit this group of patients," per a news release.The board recommended to stop enrolling new patients into the study, and this was done "immediately," according to the release.

The study launched in August 2020, and aimed to reach 900 patients across 47 hospital emergency departments (ED) in the U.S., but only enrolled 511 patients.

The concept behind the treatment is that antibodies in the plasma from recovered patients could be infused into ill patients in a bid to improve conditions.

Trial participants received one unit of plasma or a placebo, and researchers studied whether patients went on to require hospital care, sought additional care or died within 15 days of starting the trial.